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A commercial kit from Diagnostica, Inc., Miami, Fla., was studied for its ability to detect antibodies to the teichoic acids of Staphylococcus aureus. A comparative study of the Diagnostica counterimmunoelectrophoresis (CIE) system and our gel double-diffusion method was undertaken with 156 serum samples from 142 patients. Included were 25 cases of staphylococcal and non-staphylococcal endocarditis, 30 cases of S. aureus bacteremia, 19 cases of nonbacteremic S. aureus infection, 39 cases of hospitalized patients without a staphylococcal infection, and 29 normal controls. Agreement between methodologies was attained in 138 (88.5%) of the 156 samples tested and in 127 (89.4%) of the 142 patients. Of 13 patients with culture-proven S. aureus endocarditis, significant antibody titers were found in all patients (100%) by CIE and in 12 patients (92.3%) by double diffusion. No significant titers were found in normal sera by CIE, but four sera were positive by double diffusion. Of 80 sera from patients with no evidence of S. aureus infection, 4 (5.0%) were positive by CIE and 7 (8.8%) were positive by double diffusion. The Diagnostica CIE kit appears to provide a suitable means for the detection of deep-seated S. aureus infections. Assays for elevated or rising titers of teichoic acid antibodies are reported to be of value in the detection and management of deep-seated Staphylococcus aureus infections (1, 3, 5, 8, 9) such as bacterial endocarditis. Unfortunately, differences in antigen preparation and assay systems generate a certain degree of variability among reported data (11) and result in obfuscation of test usefulness. Although recent publications (7, 11) Of the 19 complicated bacteremia cases in group 2, seven patients were positive by both techniques. A significant titer was found by CIE in one patient with an infected median sternotomy site. Two other patients, one with pneumonia and one with an epidural abscess, were positive by double diffusion. Both methods detected antibodies in 1 of 11 patients with uncomplicated S. aureus bacteremia. CIE detected antibodies in one additional patient with concurrent multiple myeloma.
Both techniques detected antibodies in 3 of 19 patients with nonbacteremic staphylococcal infection (group 3). Two of these patients had osteomyelitis, whereas one had a deep wound infection. Two additional samples from a patient with an infected median sternotomy site were positive by double diffusion.
Group 4, consisting of patients with nonstaphylococcal disease, included 39 cases. One patient with a ventriculoatrial shunt infection due to microaerophilic streptococci was positive by both assays. Another patient with viral pneumonia and one with an undefined connective tissue disease were positive by CIE, and two patients with atopic dermatitis were positive by double diffusion.
In group 5, of 29 normal controls, 0 were positive by CIE, whereas 4 were positive by double diffusion. Of 80 total patients having no evidence of S. aureus infection, 4 (5.0%) were positive by CIE and 7 (8.8%) were positive by double diffusion.
DISCUSSION
The detection of antibodies to the cell wall teichoic acids of S. aureus correlates with the presence of endocarditis or other deep tissue infection (1, 3, 5, 9) . Although the test appears to be of proven value, a lack of test standardization results in some confusing variability (11) . Most commonly, the antigen is a bacterial ultrasonic extract, but others report using a lysostaphin preparation (2) or a buffer extraction (8) . Other factors that vary among procedures include the S. aureus strain used for antigen preparation, antigen concentration, agar matrix, gel diffusion or CIE, and positive control serum. Although two recent publications (7, 11) seek to improve assay standardization by technical modifications, another alternative would be the adoption of a reliable commercial test. For the past several years, a gel double-diffusion assay has been routinely used in our clinical laboratory for the detection of teichoic acid antibodies. The Diagnostica CIE kit was compared with our assay with sera from patients for whom the teichoic acid antibody test was requested, from other selected patients, and from normal controls.
Although both methods use an antigen prepared from the Lafferty strain of S. aiureuis, the tests differ in that a lysostaphin preparation was used in the double diffusion assay, whereas the Diagnostica kit used an ultrasonic extract. Sheagren et al. (7) found fewer false-negative results with an ultrasonic extract than with a lysostaphin preparation. Our investigation found no appreciable differences between the two tests in the detection of antibodies in patients with S. aureus endocarditis or complicated bacteremia. Others (1, 9, 10) also reported similar sensitivity in detecting antibodies in 90 to 100% of patients with S. aureus endocarditis and in 50% of patients with complicated bacteremia.
Since the Diagnostica kit uses CIE, its results are available within 1 to 2 h, whereas double diffusion in gel requires at least 18 h. Although more rapid to perform, CIE methods are associated with a greater frequency of false-positive reactions. This problem may be lessened by requiring a positive test to demonstrate a higher titer. This was done in both of the methods we used. A positive serum was required to have a titer of 1:2 or greater in the double-diffusion test and 1:4 or greater with the CIE kit. With these criteria, the percentage of significant antibody titers in 80 individuals with no evidence of S.
atureus infection was slightly lower for CIE (5.0%) than for double diffusion (8.8%). Other studies show similar percentages (3) (4) (5) .
In general, the double-diffusion test with the lysostaphin preparation and the CIE kit with an ultrasonic extract gave comparable results among our groups of patients. The more widespread adoption of a commercial kit may help to eliminate the problems associated with the variability of teichoic acid antibody assays.
